Alopecia Universalis in an Elderly Chinese Man Induced by Sacubitril/Alisartan, a Novel Angiotensin Receptor-Neprilysin Inhibitor

    August 2023 in “ Journal of inflammation research ”
    Yan Teng, Yu Fan, Dong Shang, Xiaohua Tao, Dongsheng Sun
    Image
    Studysummary This case report observed alopecia universalis, a complete hair loss condition, in a patient during a clinical trial with the angiotensin receptor-neprilysin inhibitor sacubitril/alisartan, indicating that ARNI therapy might be associated with such cutaneous reactions.
    Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
    A unique case of alopecia universalis was observed in an elderly Chinese man during a clinical trial involving sacubitril/alisartan, a novel angiotensin receptor-neprilysin inhibitor (ARNI). This rare adverse event, where medications trigger the premature transition of actively growing hairs into the telogen phase, adds to the spectrum of cutaneous reactions associated with ARNI therapy.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results